{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Marksans Pharma Q2 FY26: Strong Quarter Masks Underlying Concerns as FII Exit Continues
Marksans Pharma Ltd., a Mumbai-based pharmaceutical formulation manufacturer, reported a consolidated net profit of ₹98.25 crores for Q2 FY26, marking a robust 68.47% quarter-on-quarter surge from ₹58.32 crores in Q1 FY26. However, the year-on-year picture remains subdued, with profits growing just 1.58% from ₹96.72 crores in Q2 FY25. The ₹8,712 crore market capitalisation company's shares have faced persistent selling pressure, declining 37.30% over the past year despite the recent quarterly uptick, as foreign institutional investors continue reducing their stake.
How has been the historical performance of Marksans Pharma?
Marksans Pharma has shown consistent growth, with net sales increasing from INR 1,134.21 crore in March 2020 to INR 2,622.85 crore in March 2025, alongside rising profits and total assets. Despite a slight decrease in operating profit margin, the company has maintained positive cash flow from operations while investing in growth.
Is Marksans Pharma technically bullish or bearish?
As of November 13, 2025, Marksans Pharma's technical trend is mildly bearish, supported by daily moving averages and Bollinger Bands, despite some mixed signals from weekly indicators.
Marksans Pharma Experiences Mixed Technical Signals Amid Market Volatility
Marksans Pharma has experienced recent stock price fluctuations, currently priced at 187.00. The company shows mixed technical indicators, with some suggesting bullish momentum while others indicate bearish trends. Despite recent declines in year-to-date and one-year returns, the stock has demonstrated substantial growth over three and five years.
How has been the historical performance of Marksans Pharma?
Marksans Pharma has shown consistent growth in net sales and profitability, with net sales increasing from 1,000.07 Cr in Mar'19 to 2,622.85 Cr in Mar'25, and profit after tax rising from 80.44 Cr to 382.62 Cr during the same period. The company's earnings per share improved significantly from 1.97 to 8.4, reflecting strong operational efficiency and financial health.
Is Marksans Pharma technically bullish or bearish?
As of 12 November 2025, Marksans Pharma's trend is neutral with mixed signals: weekly indicators show mild bullishness while monthly indicators reflect mild bearishness, indicating a lack of clear direction.
Marksans Pharma Faces Mixed Technical Trends Amidst Market Volatility and Evaluation Revision
Marksans Pharma, a small-cap pharmaceutical company, has seen notable stock price fluctuations, with a current price of 196.60. The stock has experienced significant volatility over the past year, with a 52-week high of 358.50 and a low of 162.05, reflecting its dynamic market position.
Why is Marksans Pharma falling/rising?
As of 11-Nov, Marksans Pharma Ltd's stock price is Rs 194.40, up 3.93% today, but it has underperformed year-to-date with a decline of 34.38%. Despite short-term gains, challenges remain, including a drop in operating profit and negative long-term results.
Is Marksans Pharma technically bullish or bearish?
As of 20 October 2025, the market trend is mildly bearish, indicated by bearish signals from the weekly MACD and KST, while the monthly indicators show uncertainty with no strong bullish signals.
Is Marksans Pharma technically bullish or bearish?
As of 17 October 2025, the market trend has shifted to a bearish stance, supported by bearish signals from the MACD, KST, and moving averages, despite some mildly bullish indicators like the RSI and OBV.
Marksans Pharma Faces Mixed Technical Trends Amidst Significant Year-to-Date Decline
Marksans Pharma, a small-cap pharmaceutical company, has faced significant challenges, with a year-to-date decline of 40.32%. Despite a notable drop of 37.56% over the past year, the company has demonstrated strong long-term returns of 270.65% and 240.66% over three and five years, respectively.
Is Marksans Pharma technically bullish or bearish?
As of October 17, 2025, Marksans Pharma's technical trend is bearish with moderate strength, indicated by bearish MACD, Bollinger Bands, and moving averages, despite a mildly bullish weekly OBV.
Is Marksans Pharma technically bullish or bearish?
As of October 17, 2025, the market trend is bearish with moderate strength, indicated by bearish MACD, moving averages, and Bollinger Bands, despite a bullish RSI.
Is Marksans Pharma technically bullish or bearish?
As of 14 October 2025, Marksans Pharma's trend is mildly bearish, supported by bearish indicators like the weekly MACD and KST, despite a bullish weekly RSI, suggesting caution due to conflicting signals.
Marksans Pharma Faces Technical Trend Shifts Amid Market Volatility and Performance Discrepancies
Marksans Pharma, a small-cap pharmaceutical company, has experienced notable stock fluctuations, with a recent trading range indicating volatility. While technical indicators show mixed signals, the company has outperformed the Sensex over the past week and three years, despite a significant year-to-date decline.
Is Marksans Pharma overvalued or undervalued?
As of October 10, 2025, Marksans Pharma is considered overvalued with a PE ratio of 23.52 and a year-to-date decline of 38.65%, contrasting with the Sensex's 5.58% return.
Is Marksans Pharma overvalued or undervalued?
As of October 10, 2025, Marksans Pharma is considered overvalued with a PE ratio of 23.52 and a year-to-date return of -38.65%, contrasting sharply with the Sensex's positive performance.
Is Marksans Pharma overvalued or undervalued?
As of October 10, 2025, Marksans Pharma is considered overvalued with a PE ratio of 23.52 and a PEG ratio of 4.80, despite outperforming the Sensex in the past three years, it has recently declined by 38.65% year-to-date compared to the Sensex's 5.58% gain.
Why is Marksans Pharma falling/rising?
As of 10-Oct, Marksans Pharma Ltd is currently priced at Rs 181.75, reflecting a 7.32% increase today and strong short-term performance, but it has faced long-term challenges with a -36.65% return over the past year. Despite recent gains and increased investor participation, the stock's long-term volatility and poor growth metrics may limit enthusiasm.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
